PEG-IFNα

DRUG9 trials

Conditions

Anti-PD-1 AntibodyAnti-PD-L1 AntibodyChronic Hepatitis BChronic Hepatitis B Virus (HBV) InfectionChronic Hepatitis B Virus InfectionChronic Hepatitis bFor Treatment of Chronic Hepatitis B Virus InfectionHepatitis B, Chronic

Phase 1

A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection

CompletedNCT05612581

Vir Biotechnology, Inc.Hepatitis B, Chronic

Start: 2023-05-10End: 2025-08-19Updated: 2026-02-09

Phase 2

A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection

TerminatedNCT04781647

Assembly BiosciencesChronic Hepatitis B

Start: 2021-02-18End: 2022-12-02Updated: 2023-10-06

Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

CompletedNCT04856085

Vir Biotechnology, Inc.Hepatitis B, Chronic

Start: 2021-07-11End: 2026-03-16Updated: 2026-04-23

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)

RecruitingNCT05771402

The Second Affiliated Hospital of Chongqing Medical UniversityAnti-PD-1 Antibody, Chronic Hepatitis b, Peg-IFNα

Start: 2023-10-10End: 2026-12-31Target: 120Updated: 2026-09-04

Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV Patients

CompletedNCT05970289

Brii Biosciences LimitedChronic Hepatitis B Virus Infection

Start: 2023-08-22End: 2026-01-23Updated: 2026-10-20

Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)

CompletedNCT06491563

Brii Biosciences LimitedFor Treatment of Chronic Hepatitis B Virus Infection

Start: 2024-08-06End: 2026-08-05Updated: 2026-10-21

A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNα in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)

RecruitingNCT06650852

Brii Biosciences LimitedChronic Hepatitis B Virus (HBV) Infection

Start: 2024-10-31End: 2029-09-01Target: 250Updated: 2026-10-22

A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (B)

RecruitingNCT07845058

The Second Affiliated Hospital of Chongqing Medical UniversityAnti-PD-1 Antibody, Anti-PD-L1 Antibody, Chronic Hepatitis B +1

Start: 2023-10-10End: 2026-12-31Target: 1200Updated: 2026-09-28

Phase 4

ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

RecruitingNCT07573943

The Second Affiliated Hospital of Chongqing Medical UniversityChronic Hepatitis b

Start: 2024-05-21End: 2026-12-31Target: 120Updated: 2026-09-01

Related Papers

Elebsiran and PEG-IFNα for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial.